Performance of first-trimester combined screening for trisomy 13 and 18 with the double test taken at a gestational age of 8 + 0 to 13 + 6

Prenatal Diagnosis

Volumn 29, Issue 6, 2009, Pages 582-587

  Kirkegaard, Ida ^a   Petersen, Olav Bjørn ^a   Uldbjerg, Niels ^a   Tørring, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chromosomal abnormalities; Consecutive combined test; Double test; First trimester screening; Trisomy 13 18

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; KARYOTYPE; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 13; TRISOMY 18;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; FEMALE; GESTATIONAL AGE; HUMANS; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; TRISOMY;

EID: 67049108869     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2254     Document Type: Article

References (27)

1. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. 2005. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 192(6): 1761-1767.
2. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. Onestop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20(3): 219-225.
3. Christiansen M, Jaliashvili I. 2003. Total pregnancy-associated plasma protein A-a first trimester maternal serum marker for Down's syndrome: clinical and technical assessment of a polymonoclonal enzyme immunoassay. Scand J Clin Lab Invest 63(6): 407-415.
4. Cuckle HS, van Lith JM. 1999. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 19(6): 505-512.
5. Jaques AM, Halliday JL, Francis I, et al. 2007. "Follow up and evaluation of the Victorian first-trimester combined screening programme for Down syndrome and trisomy 18. BJOG 114(7): 812-818.
6. Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH. 2008. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 32(4): 488-492.
7. Kirkegaard I, Petersen OB, Uldbjerg N, Tørring N. 2008. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat Diagn 28(9): 839-844.
8. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. 2000. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96(2): 207-213.
9. Malone FD, Canick JA, Ball RH, et al. 2005. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353(19): 2001-2011.
10. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25(3): 221-226.
11. Rasmussen SA, Wong LY, Yang Q, May KM, Friedman JM. 2003. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 111(4 Pt 1): 777-784.
12. Schiøtt KM, Christiansen M, Petersen OB, Sørensen TL, Uldbjerg N. 2006. The "Consecutive Combined Test" - using double test from week 8 + 0 and nuchal translucency scan, for first trimester screening for Down syndrome. Prenat Diagn 26(12): 1105-1109.
13. Snijders RJ, Sebire NJ, Nicolaides KH. 1995. Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 10(6): 356-367.
14. Spencer K. 2002. Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. Prenat Diagn 22(3): 244-246.
15. Spencer K, Crossley JA, Aitken DA, Nicolaides KH. 2005. Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13. Prenat Diagn 25(5): 358-361.
16. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. 2002. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 39(Pt 6): 567-576.
17. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. 2003a. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 40(Pt 3): 219-231.
18. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003b. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 110(3): 281-286.
19. Spencer K, Crossley JA, Green K, Worthington DJ, Brownbill K, Aitken DA. 1999. Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn 19(12): 1127-1134.
20. Spencer K, Nicolaides KH. 2002. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 22(10): 877-879.
21. Spencer K, Ong C, Skentou H, Liao AW, Nicolaides H. 2000a. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20(5): 411-416.
22. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000b. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 107(10): 1271-1275.
23. Tørring N, Jølving LR, Petersen OB, Holmskov A, Hertz JM, Uldbjerg N. 2008. Prenatal diagnostics in Arhus and Viborg Counties after implementation of first trimester risk assessment. Ugeskr Læger 170(1): 50-54.
24. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19(11): 1035-1042.
25. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10(2): 56-104.
26. Wapner R, Thom E, Simpson JL, et al. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349(15): 1405-1413.
27. Wøjdemann KR, Shalmi AC, Christiansen M, et al. 2005. "Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 25(3): 227-233.